Advanced Search
GU Nian, SHENG Xinyi, QIN Chao, CHEN Jintuo, XU Siyuan, YIN Lifang. Preparation and gastrointestinal absorption kinetics of tacrolimus solid dispersion[J]. Journal of China Pharmaceutical University, 2016, 47(6): 694-701. DOI: 10.11665/j.issn.1000-5048.20160611
Citation: GU Nian, SHENG Xinyi, QIN Chao, CHEN Jintuo, XU Siyuan, YIN Lifang. Preparation and gastrointestinal absorption kinetics of tacrolimus solid dispersion[J]. Journal of China Pharmaceutical University, 2016, 47(6): 694-701. DOI: 10.11665/j.issn.1000-5048.20160611
shu

Preparation and gastrointestinal absorption kinetics of tacrolimus solid dispersion

More Information
    Graphical Abstract
    • Abstract
  • To prepare tacrolimus solid dispersion to increase the solubility and bioavailability of tacrolimus. Tacrolimus solid dispersions were prepared by different water-soluble carriers, which were evaluated by in vitro drug dissolutions to select the optimal formulation. The optimal tacrolimus solid dispersion was evaluated by scanning electron microscopy(SEM), X-ray diffraction(XRD)and differential scanning calorimetry(DSC), and its gastrointestinal absorption kinetics was studied in rats. The results showed that tacrolimus solid dispersion with HPMC E3 as carrier had the fastest dissolution rate. SEM, XRD and DSC studies indicated that tacrolimus was distributed within the carrier HPMC E3 in amorphous form. Gastrointestinal absorption experiments in rats demonstrated that the optimal formulation remarkably increased oral absorption of tacrolimus. These results demonstrate that a novel tacrolimus solid dispersion with HPMC E3 as carrier may be an advantageous dosage form of tacrolimus, boosting the solubility and absorption in gastrointestinal tract.
    • FullText(HTML)
    • References (8)
  • [1]
    Liu F, Wei JF, Meng L, et al. New development in macrolide immunosuppressant[J].Chin New Drugs J(中国新药杂志),2014,22(1):61-66.
    [2]
    Liu YS,Gao S,Ke X,et al.Recent research advances in solid dispersions of poorly soluble drugs[J].Prog Pharm Sci(药学进展),2013,37(4):166-173.
    [3]
    Yan F,Ke X,Ping QN,et al.Preparation of baicalein solid dispersions and oral bioavailability in rats[J].J China Pharm Univ(中国药科大学学报),2008,39(5):406-411.
    [4]
    Zhang Q, Zhang MX, Zhang J, et al. Studies on the intestinal absorption kinetics of tacrolimus in rats[J].Chin Hosp Pharm J(中国医院药学杂志),2010,30(8):639-642.
    [5]
    Veloxis Pharma Inc.Modified release tacrolimus compositions:CN,1859910A[P].2006-11-08[2016-03-11] .
    [6]
    Arik D, Brady T, Gordon L, et al. Segmental-dependent membrane permeability along the intestine following oral drug administration:evaluation of a triple single-pass intestinal perfusion(TSPIP)approach in the rat[J].Eur J Pharm Sci,2009,36:320-329.
    [7]
    Ying J,Lyu Y,Du GH.New development in amorphous drug[J].Acta Pharm Sin(药学学报),2009,44(5):443-448.
    [8]
    Astellas Pharma Inc.Tacrolimus sustained release pharmaceutical composition:EP,2119442A[P].2009-11-18[2016-03-11] .
    • Related Articles

  • Related Articles

    [1]YAO Lei, QU Linlin, FAN Daidi. Effects of rare ginsenoside on idiopathic pulmonary fibrosis[J]. Journal of China Pharmaceutical University, 2023, 54(5): 607-613. DOI: 10.11665/j.issn.1000-5048.2023042002
    [2]HUANG Zhicheng, YE Liu, DU Yu, GU Hongfeng, GAO Fanyun, ZHU Qihua, XU Yungen. Design, synthesis and biological evaluation of PARP-1/PI3K dual-target inhibitors[J]. Journal of China Pharmaceutical University, 2023, 54(4): 450-460. DOI: 10.11665/j.issn.1000-5048.2023050301
    [3]WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405
    [4]LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602
    [5]KE Ke, JIANG Wenli, WANG Yu, ZHU Jingyu, JIN Jian. Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65[J]. Journal of China Pharmaceutical University, 2019, 50(4): 410-416. DOI: 10.11665/j.issn.1000-5048.20190405
    [6]CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]WAN Aini, XU Dongsheng, CAI Yanfei, CHEN Yun, JIN Jian, LI Huazhong. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J]. Journal of China Pharmaceutical University, 2017, 48(4): 476-482. DOI: 10.11665/j.issn.1000-5048.20170413
    [9]DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14，a novel nitric oxide donating biphenyldicarboxylate derivative，on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257.
    [10]Danshen Inhibiting Isoproterenol Induced Cardiac Hypertrophy and Fibrosis in Mice and its Mechanisms[J]. Journal of China Pharmaceutical University, 2003, (6): 84-87.

Catalog

    Get Citation
    PDF
    XML
    Article views (839) PDF downloads (2016) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：454423

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return